Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 22/07/20241 min de leitura
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.
Idioma original da fonte: Federal Register — Food and Drug AdministrationAbrir o comunicado original →